Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer

Por Witteveen, Petronella O, van der Mijn, Koen JC, Los, Maartje, Kronemeijer, Roelien H, Groenewegen, Gerard, Voest, Emile E
Publicado em 2010

Patients’ Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist’s Awareness of These Preferences

Por Oostendorp, Linda J. M., Ottevanger, Petronella B., van de Wouw, Agnes J., Honkoop, Aafke H., Los, Maartje, van der Graaf, Winette T. A., Stalmeier, Peep F. M.
Publicado no J Cancer Educ (2015)

Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study

Por May, Anne M, Bosch, Marcel J C, Velthuis, Miranda J, van der Wall, Elsken, Steins Bisschop, Charlotte N, Los, Maartje, Erdkamp, Frans, Bloemendal, Haiko J, de Roos, Marnix A J, Verhaar, Marlies, ten Bokkel Huinink, Daan, Peeters, Petra H M, de Wit, G Ardine
Publicado no BMJ Open (2017)

Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial

Por Travier, Noémie, Velthuis, Miranda J., Steins Bisschop, Charlotte N., van den Buijs, Bram, Monninkhof, Evelyn M., Backx, Frank, Los, Maartje, Erdkamp, Frans, Bloemendal, Haiko J., Rodenhuis, Carla, de Roos, Marnix A.J., Verhaar, Marlies, ten Bokkel Huinink, Daan, van der Wall, Elsken, Peeters, Petra H.M., May, Anne M.
Publicado no BMC Med (2015)